Role of phytotherapy in men with lower urinary tract symptoms

Current Opinion in Urology

Volumn 15, Issue 1, 2005, Pages 45-48

  Yan, Kit Fong ^a   Milani, Shirin ^a   Djavan, Bob ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Efficacy; Progression; Serenoa repens; Tolerability

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; PLACEBO; SABAL EXTRACT;

CLINICAL TRIAL; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SABAL; SEXUAL DYSFUNCTION; URINARY TRACT DISEASE; URINE FLOW RATE;

HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; RECEPTORS, ADRENERGIC, ALPHA-1; SERENOA; TESTOSTERONE 5-ALPHA-REDUCTASE; UROLOGIC DISEASES;

EID: 12144272581     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200501000-00011     Document Type: Review

References (23)

1. Sagnier PP, Girman CJ, Garraway M, et al. International comparisons of the community prevalence of symptoms of prostatism in four countries. Eur Urol 1996; 29:15-20.
2. Lanes SF, Sulsky S, Walker AM, et al. A cost density analysis of benign prostatic hyperplasia. Clin Ther 1996; 18:993-1004.
3. Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998; 279:1548-1553.
4. Wilt TJ, Ishani A, Stark G, et al. Saw Palmetto extracts for treatment of benign prostatic hyperplasia. JAMA 1998; 280:1604-1609.
5. R): a 5α-reductase types I and II inhibitor: new evidence in a coculture model of BPH. Prostate 1999; 40:232-241.
6. R) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994; 26:247-252.
7. R) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998; 37:77-83.
8. Carilla E, Briley M, Fauran F, et al. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cystosolic androgen receptor in rat prostate. J Steroid Biochem 1984; 20:521-523.
9. Veltri RW, Marks LS, Miller MC, et al. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. Urology 2002; 60:617-622.
10. Di Silverio F, D'Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992; 21:309-314.
11. Goepel M, Hecker U, Krege S, et al. Saw palmetto extracts potently and noncompetively inhibit human alpha-1-adrenoreceptors in vitro. Prostate 1999; 38:208-215.
12. Paubert-Braquet M, Menica Hueta JM, Gousse H, et al. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty acids 1997; 57:299-304.
13. Paubert-Braquet M, Cousse H, Raynaud JP, et al. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostatic biopsies. Eur Urol 1998; 33:340-347.
14. Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996; 9:379-395.
15. Vacher P, Prevarskaya N, Shyrma R, et al. The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biochem Sci 1995; 2:357-365.
16. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000; 55:533-539.
17. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001; 58:960-965.
18. Willetts KE, Clements MS, Champion S, et al. Serenoa repens extract for benign prostatic hyperplasia: a randomized controlled trial. BJU Int 2003; 92:267-270.
19. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate 1996; 29:231-240.
20. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002; 41:497-507.
21. Debruyne F, Boyle P, Da Silva FC, et al. Evaluation of the clinical benefit of Permixon and Tamsulosin in severe BPH patients - PERMAL study subset analysis. Eur Urol 2004; 45:773-780. This is the first study to compare phytotherapy and alpha adrenoreceptor antagonist for treatment of severe BPH.
22. Djavan B, Seitz C, Dobrovits M, et al. Multicenter European prospective comparative study of phyotherapy and watchful waiting in men with mild symptoms of bladder outlet obstruction: can progression be delayed or prevented? J Urol 2004; 171: 244, A920. This is the longest trial that assesses the efficacy of Serenoa repens in men with mild symptoms of bladder outlet obstruction.
23. Gerber GS, Fitzpatrick JM. The role of lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia. BJU Int 2004; 94:338-344. This is a good review on phytotherapy for management of BPH.